Improved pathology reporting in NAFLD/NASH for clinical trials
J Clin Pathol
.
2022 Feb;75(2):73-75.
doi: 10.1136/jclinpath-2021-207967.
Epub 2021 Nov 9.
Authors
Caitlin Rose Langford
1
,
Marc H Goldinger
2
,
Darren Treanor
3
4
,
Clare McGenity
3
4
,
Jonathan R Dillman
5
6
,
Daniela S Allende
7
,
Robert Goldin
8
,
Elizabeth M Brunt
9
,
Kurt Zatloukal
10
,
Helmut Denk
10
,
Kenneth A Fleming
2
11
Affiliations
1
Perspectum Ltd, Oxford, UK caitlin.langford@perspectum.com.
2
Perspectum Ltd, Oxford, UK.
3
Pathology, University of Leeds, Leeds, UK.
4
Department of Histopathology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
5
Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
6
Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
7
Department of Anatomical Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
8
Section for Pathology, Imperial College, London, UK.
9
Department of Pathology and Immunology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA.
10
Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
11
Green Templeton College, University of Oxford, Oxford, UK.
PMID:
34753791
PMCID:
PMC8788244
DOI:
10.1136/jclinpath-2021-207967
No abstract available
Keywords:
gastrointestinal diseases; liver; liver diseases; research report; safety.
MeSH terms
Clinical Trials as Topic
Humans
Liver / pathology
Non-alcoholic Fatty Liver Disease / pathology*
Research Report*